BioPlus
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BioPlus makes hyaluronic acid-based medical products, including dermal fillers (injectable gels used to smooth wrinkles), surgical anti-adhesion barriers, and joint and bladder tissue-repair devices, as well as bio-cosmetics and biopharmaceuticals developed through gene-recombination technology.
Its products are used by medical and aesthetic professionals, and it supplies both domestic and international markets through direct sales and distribution partners. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core revenue is anchored in its filler and tissue-repair device lines, while it is actively expanding into biopharmaceuticals, bio-cosmetics, and biological raw ingredients.
Summary is AI-generated and may contain errors · figures from DART filings
BioPlus has established an overseas subsidiary in Hainan, China, to build local production facilities and an aesthetic-medicine platform targeting China and neighbouring markets.
BioPlus in five facts
What does BioPlus do?
BioPlus makes hyaluronic acid-based medical products, including dermal fillers (injectable gels used to smooth wrinkles), surgical anti-adhesion barriers, and joint and bladder tissue-repair devices, as well as bio-cosmetics and biopharmaceuticals developed through gene-recombination technology.
Where is BioPlus listed and in which sector?
BioPlus (Korean name: 바이오플러스) trades under KRX code 099430 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is BioPlus?
Its market capitalisation was US$166.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were BioPlus's latest annual revenue and operating profit?
For fiscal year 2025, BioPlus reported revenue of US$68.6M, operating profit of US$11.3M and net income of US$15.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 36.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 8
- Cash/in-kind dividend decision
BioPlus declared a cash dividend of US$0.05 per share.
Dividend · Feb 13 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
BioPlus reported consolidated results for FY2025: revenue of US$63.1M (+36.87% year on year), operating profit of US$10.4M (−36.6% year on year) and net income of US$13.9M (+14.2% year on year).
Earnings · Feb 13 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 2